U.S. stocks rise on U.S.-Japan trade deal optimism; Tesla, Alphabet earnings due
RICHMOND, VA - Indivior PLC (NASDAQ/LSE:LON:INDV) has appointed Tony Kingsley to its Board of Directors as an Independent (LON:IOG) Non-Executive Director, effective July 1, 2025, according to a company press release.
Kingsley, currently CEO and Director of biotechnology company Stablix, Inc., was appointed pursuant to Indivior’s relationship agreement with affiliates of Oaktree Capital Management, L.P.
David Wheadon, Chair of Indivior’s Board, cited Kingsley’s "strategic vision, operational expertise, and ability to drive growth in complex, regulated environments" as valuable assets for the company, which specializes in treatments for opioid use disorder.
Prior to his role at Stablix, Kingsley served as President and CEO of Scholar Rock (NASDAQ:SRRK) and TARIS Bio, which was acquired by Janssen Pharmaceuticals in 2019. His career also includes executive positions at The Medicines Company and Biogen (NASDAQ:BIIB), where he oversaw multiple therapy launches.
Kingsley holds a magna cum laude degree from Dartmouth College and an M.B.A. from Harvard Business School.
Indivior, headquartered in Richmond, Virginia, develops and markets treatments for opioid use disorder. The company employs over 1,000 people globally and offers its portfolio of products in more than 30 countries worldwide.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.